The clinical value and the cost-effectiveness of follow-up in endometrial cancer patients

International Journal of Gynecological Cancer

Volumn 14, Issue 5, 2004, Pages 931-937

  Tjalma, Wiebren A A ^a   Van Dam, P A ^b   Markar, A P ^c   Cruickshank, D J ^d  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b SINT AUGUSTINUS HOSPITAL   (Belgium)

^c MIDDELHEIM HOSPITAL   (Belgium)

^d JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Cost effectiveness; Endometrial cancer; Follow up; Survival

Indexed keywords

CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; ENDOMETRIUM CANCER; EVIDENCE BASED MEDICINE; FOLLOW UP; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; PERIODIC MEDICAL EXAMINATION; PRIORITY JOURNAL; REVIEW; SYMPTOM;

COST-BENEFIT ANALYSIS; DIAGNOSTIC IMAGING; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; NEOPLASM RECURRENCE, LOCAL; PHYSICAL EXAMINATION; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 4544264452     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1048-891X.2004.014532.x     Document Type: Review

References (26)

1. Podczaski E, Kaminski P, Gurski K et al. Detection and patterns of treatment failure in 300 consecutive cases of "early" endometrial cancer after primary surgery. Gynecol Oncol 1992;47:323-7.
2. Shumsky AG, Stuart GC, Brasher PM, Nation JG, Robertson DI, Sangkarat S. An evaluation of routine follow-up of patients treated for endometrial carcinoma. Gynecol Oncol 1994;55:229-33.
3. Berchuck A, Anspach C, Evans AC et al. Postsurgical surveillance of patients with FIGO stage I/II endometrial adenocarcinoma. Gynecol Oncol 1995;59:20-4.
4. Reddoch JM, Burke TW, Morris M, Tornos C, Levenback C, Gershenson DM. Surveillance for recurrent endometrial carcinoma: development of a follow-up scheme. Gynecol Oncol 1995;59:221-5.
5. Owen P, Duncan ID. Is there any value in the long term follow up of women treated for endometrial cancer? Br J Obstet Gynaecol 1996;103:710-3.
6. Allsop JR, Preston J, Crocker S. Is there any value in the long-term follow up of women treated for endometrial cancer? Br J Obstet Gynaecol 1997;104:122.
7. Salvesen HB, Akslen LA, Iversen T, Iversen OE. Recurrence of endometrial carcinoma and the value of routine follow up. Br J Obstet Gynaecol 1997;104:1302-7.
8. Agboola OO, Grunfeld E, Coyle D, Perry GA. Costs and benefits of routine follow-up after curative treatment for endometrial cancer. CMAJ 1997;157:879-86.
9. Ng TY, Ngan HY, Cheng DK, Wong LC. Vaginal vault cytology in the routine follow-up of patients treated for endometrial carcinoma: is it useful? Aust N Z J Obstet Gynaecol 1997;37:104-6.
10. Gadducci A, Cosio S, Fanucchi A, Cristofani R, Genazzani AR. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer. Anticancer Res 2000;20:1977-84.
11. Morice P, Levy-Piedbois C, Ajaj S et al. Value and cost evaluation of routine follow-up for patients with clinical stage I/II endometrial cancer. Eur J Cancer 2001;37: 985-90.
12. Otsuka I, Ono I, Akamatsu H, Sunamori M, Aso T. Pulmonary metastasis from endometrial carcinoma. Int J Gynecol Cancer 2002;12:208-13.
13. Connor JP, Andrews JI, Anderson B, Buller RE. Computed tomography in endometrial carcinoma. Obstet Gynecol 2000;95:692-6.
14. Niloff JM, Klug TL, Schaetzl E, Zurawski VR, Knapp RC, Bast RC Jr. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol 1984;148:1057-8.
15. Duk JM, Aalders JG, Fleuren GJ, de Bruijn HW. CA 125: a useful marker in endometrial carcinoma. Am J Obstet Gynecol 1986;155:1097-102.
16. Rose PG, Reale FR, Beurskens ML, Hunter RE. Preoperative CA-125 levels predict poor prognostic pathologic features in early stage, FIGO grade 1 and 2 endometrial adenocarcinoma. Int J Gynecol Cancer 1993;3:259-63.
17. Beck EP, Wagner M, Anselmino L, Xu F, Bast RC, Jaeger W. Is OVX1 a suitable marker for endometrial cancer? Gynecol Oncol 1997;65:291-6.
18. Lo SS, Cheng DK, Ng TY, Wong LC, Ngan HY. Prognostic significance of tumour markers in endometrial cancer. Tumour Biol 1997;18:241-9.
19. Patsner B, Orr JW, Mann WJ Jr. Use of serum CA 125 measurement in posttreatment surveillance of early-stage endometrial carcinoma. Am J Obstet Gynecol 1990;162:427-9.
20. Rose PG, Sommers RM, Reale FR, Hunter RE, Fournier L, Nelson BE. Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma. Obstet Gynecol 1994;84:12-6.
21. Olaitan A, Murdoch J, Anderson R, James J, Graham J, Barley V. A critical evaluation of current protocols for the follow-up of women treated for gynecological malignancies: a pilot study. Int J Gynecol Cancer 2001;11:349-53.
22. Shumsky AG, Brasher PM, Stuart GC, Nation JG. Risk-specific follow-up for endometrial carcinoma patients. Gynecol Oncol 1997;65:379-82.
23. Ohlsson B, Breland U, Ekberg H, Graffner H, Tranberg KG. Follow-up after curative surgery for colorectal carcinoma: randomized comparison with no follow-up. Dis Colon Rectum 1995;38:619-26.
24. Kjeldsen BJ, Kronborg O, Fenger C, Jorgensen OD. A prospective randomized study of follow-up after radical surgery for colorectal cancer. Br J Surg 1997;84:666-9.
25. Gulliford T, Opomu M, Wilson E, Hanham I, Epstein R. Popularity of less frequent follow-up for breast cancer in randomised study: initial findings from the hotline study. BMJ 1997;314:174-7.
26. Grunfeld E, Mant D, Yudkin P et al. Routine follow-up of breast cancer in primary care: a randomised trial. BMJ 1996;313:665-9.